Table 1

Baseline variables for participants included in this analysis (n=1664) by year 5 survival status

VariableTotal cohort
(n=1664)
Year 5 outcome
Survived
(n=1375)
Died
(n=289)
Female gender (%)1010 (60.7)880 (64.0)130 (45.0)*
Age (years)73.0±8.971.8±8.878.5±7.2*
CKD-EPI eGFR (mL/min/1.73 m2)53.7±11.955.1±11.746.7±9.9*
uACR (mg/mmol)0.3 (0.0–1.5)0.3 (0.0–1.2)0.9 (0.1–3.6)*
Diabetes (%)275 (16.5)213 (15.5)62 (21.5)*
CVD (%)374 (22.5)263 (19.1)111 (38.4)*
Current or previous smoker (%)903 (54.3)713 (51.9)190 (65.7)*
ACE/ARB use (%)1074 (64.5)875 (63.6)199 (68.9)
Weight (kg)78.1±15.478.3±15.077.6±17.3
BMI (kg/m2)29.0±5.129.1±5.028.4±5.4*
Waist:hip ratio0.91±0.090.90±0.090.93±0.09*
SBP (mm Hg)134.0±18.4133.8±17.7135.6±21.3
DBP (mm Hg)72.8±11.073.3±10.970.3±11.2*
Haemoglobin (g/dL)13.2±1.413.3±1.412.8±1.6*
Corrected calcium (mmol/L)2.38±0.102.38±0.102.37±0.10
Phosphate (mmol/L)1.11±0.181.11±0.171.11±0.19
Albumin (g/L)40.7±3.240.8±3.139.7±3.4*
Bicarbonate (mmol/L)25.5±2.725.6±2.525.5±3.1
Total cholesterol (mmol/L)4.8±1.194.8±1.24.5±1.1*
Urate (μmol/L)384±91379±88408±99*
FGF23 (pg/mL)42 (33–53)42 (33–52)45 (34–59)*
PTH (pg/mL)46 (34–66)45 (33–62)56 (39–86)*
25(OH) Vitamin D (nmol/L)53 (38–71)54 (39–72)48 (31–67)*
On vitamin D supplementation (%)67 (4.0)49 (3.6)18 (6.2)*
  • Data are number (%), mean ± SD or median (IQR).

  • End of year 5 follow-up period defined as 31 April 2015.

  • *p value < 0.05, versus group who survived to end of year 5 follow-up.

  • ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CKD-EPI eGFR, chronic kidney disease epidemiology collaboration estimated glomerular filtration rate; CVD, cardiovascular disease; DBP, diastolic blood pressure; FGF, fibroblast growth factor; PTH, parathyroid hormone; SBP, systolic blood pressure; uACR, urinary albumin to creatinine ratio; 25(OH) Vitamin D, 25-hydroxy-Vitamin D.